A phase I study evaluating COM701 in patients with advanced solid tumors.

被引：0
|
作者：
Rasco, Drew W.
Vaena, Daniel A.
Sullivan, Ryan J.
Luke, Jason J.
ElNaggar, Adam
Hunter, John
Adewoye, Adeboye H.
Olweny, Judy
Patnaik, Amita
Hamilton, Erika Paige
机构：
[1] START, San Antonio, TX USA
[2] West Canc Ctr, Memphis, TN USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[5] Compugen USA Inc, San Francisco, CA USA
[6] Tennessee Oncol PLLC, Nashville, TN USA
[7] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS2657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2657
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors.
    Dudek, A
    Larson, T
    Mellskog, CE
    Bloss, LP
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 162S - 162S
  • [22] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [23] A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.
    Sandler, Alan
    Taylor, Matthew Hiram
    Urba, Walter John
    Omuro, Antonio Marcilio Padula
    Anderson, Barry Douglas
    Hansen, Daniel
    Fisher, Brenda
    Claeys, Alisa J.
    Greathouse, Amy
    McLean, Sean
    Karmali, Rashida A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] A phase I study of PT-112 in advanced solid tumors.
    Karp, Daniel D.
    Camidge, D. Ross
    Bryce, Alan Haruo
    Jimeno, Jose
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase I study of pazopanib and ixabepilone in patients with solid tumors.
    Ganesan, Chitra
    Obulareddy, J.
    Bliss, Robin L.
    Dudek, Arkadiusz Z.
    CANCER RESEARCH, 2013, 73 (08)
  • [26] A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.
    Townsley, C. A.
    Siu, L. L.
    Pedro-Salcedo, M. San
    Liu, L.
    Wakelee, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase I clinical and pharmacokinetic study of irofulven in combination with oxaliplatin in patients with advanced solid tumors.
    Alexandre, J
    Tchen, N
    Berthault-Cvitkovic, F
    Misset, JL
    Benettaib, B
    Kahatt, C
    Raymond, E
    Weems, G
    MacDonald, JR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9057S - 9057S
  • [28] COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).
    Vaena, Daniel A.
    Fleming, Gini F.
    Chmielowski, Bartosz
    Sharma, Manish
    Hamilton, Erika P.
    Sullivan, Ryan J.
    Shepard, Dale Randall
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    ElNaggar, Adam
    Adewoye, Adeboye H.
    Smith, Robina
    Lim, Emerson A.
    Dumbrava, Ecaterina Elena
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors.
    Ma, CX
    Croghan, G
    Reid, J
    Hanson, L
    Mandrekar, S
    Marks, R
    Adjei, A
    Furth, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [30] Results of phase I clinical trials of Coramsine in patients with advanced solid tumors.
    Millward, M.
    Powell, A.
    Daly, P.
    Tyson, S.
    Ferguson, R.
    Carter, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 96S - 96S
12345